STOCK TITAN

Ginkgo Bioworks Holdings, Inc. - $DNA STOCK NEWS

Welcome to our dedicated page for Ginkgo Bioworks Holdings news (Ticker: $DNA), a resource for investors and traders seeking the latest updates and insights on Ginkgo Bioworks Holdings stock.

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is pioneering the field of synthetic biology by providing an innovative horizontal platform for cell programming. Specializing in flexible, end-to-end services, the company addresses diverse challenges across multiple sectors including food, agriculture, pharmaceuticals, industrial chemicals, and specialty chemicals. Ginkgo Bioworks is organized into two primary segments: Cell Engineering and Biosecurity, with the latter contributing the majority of the company's revenue through data analytics and related services.

One of Ginkgo Bioworks' recent highlights includes the acquisition of AgBiome's platform assets, significantly enhancing its R&D capabilities in agricultural biotechnology. This move has expanded Ginkgo's proprietary metagenomics database, creating a rich resource for AI model development. Furthermore, the company is actively engaged in partnerships to amplify its technological reach, such as its collaboration with Il Granaio delle Idee to enhance sourdough bakery strains and with GreenLab to produce brazzein, a high-intensity sweetener, on a commercial scale.

Ginkgo Bioworks is also a key player in biosecurity, developing advanced infrastructure and technologies to predict, detect, and respond to biological threats. The company's upcoming Biofab1, a fully integrated lab data center expected to open in mid-2025, is part of its strategic plan to streamline operations and achieve adjusted EBITDA breakeven by the end of 2026.

Additionally, Ginkgo's platform is making significant strides in the AI and data generation space, offering services that help clients leverage high-quality data for more effective R&D. Notably, the company recently hosted its 5th annual Ferment conference, where it showcased new products and technological advancements to a global audience.

Despite facing some financial challenges, including a need to regain compliance with NYSE listing standards due to stock price fluctuations, Ginkgo remains committed to its mission. The company continues to innovate and form strategic partnerships, such as its recent agreement with Sojitz Corporation to penetrate the Japanese market, enhancing its role in the global bioeconomy.

For more information, visit ginkgobioworks.com or follow them on social media platforms like X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), and LinkedIn.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.46%
Tags
covid-19
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.93%
Tags
partnership
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.95%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
partnership

FAQ

What does Ginkgo Bioworks do?

Ginkgo Bioworks specializes in synthetic biology, providing end-to-end cell programming services across diverse sectors including food, agriculture, pharmaceuticals, industrial chemicals, and specialty chemicals.

What are the main segments of Ginkgo Bioworks?

The company is organized into two primary segments: Cell Engineering and Biosecurity, with Biosecurity generating the majority of revenue.

What recent acquisitions has Ginkgo Bioworks made?

Ginkgo recently acquired AgBiome's platform assets, which include over 115,000 fully sequenced strains and 500 million unique gene sequences, enhancing its R&D capabilities in agricultural biotechnology.

What is Biofab1?

Biofab1 is Ginkgo's new fully integrated lab data center, expected to open in mid-2025. It aims to consolidate Foundry operations to enhance efficiency and achieve financial targets.

Who are Ginkgo Bioworks' partners?

Ginkgo has partnered with companies like Il Granaio delle Idee for bakery strain development and GreenLab for brazzein production. They also have a strategic agreement with Sojitz Corporation to expand in the Japanese market.

What is Ginkgo's role in biosecurity?

Ginkgo Biosecurity develops advanced infrastructure and technologies to predict, detect, and respond to biological threats, supporting global leaders in managing biological risks.

How is Ginkgo integrating AI in its operations?

Ginkgo leverages high-quality data and AI for more effective R&D, helping clients improve data models and bioengineering processes.

What financial challenges is Ginkgo facing?

Ginkgo needs to regain NYSE compliance due to stock price fluctuations but is taking measures to streamline operations and target adjusted EBITDA breakeven by the end of 2026.

How can I stay updated with Ginkgo Bioworks' latest news?

For the latest updates, you can visit their website at ginkgobioworks.com or follow them on social media platforms like X, Instagram, Threads, and LinkedIn.

When is Ginkgo's next financial update?

Ginkgo plans to host a presentation and Q&A session reviewing business performance for the first quarter on May 9, 2024. Details will be available on their investor relations website.

Ginkgo Bioworks Holdings, Inc.

Nasdaq:DNA

DNA Rankings

DNA Stock Data

938.47M
1.33B
6.49%
82.87%
12.41%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
BOSTON